Butterfly Network Inc. (NYSE: BFLY), a digital health company pioneering portable ultrasound technology, saw its stock soar 5.31% on Wednesday after its third-generation handheld ultrasound device, Butterfly iQ3, was honored with the Best Medical Technology Award at the 2024 Prix Galien USA Awards.
The Prix Galien Awards, regarded as the "Nobel Prize of Life Sciences," recognize outstanding achievements in improving global human health through innovative drugs and treatments. Butterfly's recognition highlights the company's commitment to making ultrasound imaging more affordable, sustainable, and scalable through its pioneering Ultrasound-on-Chip technology.
The Butterfly iQ3 represents a leap forward in ultrasound technology, offering clinicians portable, semiconductor-based imaging with premium handheld quality. Built on Butterfly's proprietary P4.3 semiconductor – its most powerful Ultrasound-on-Chip platform to date – the iQ3 represents a digital revolution in the ultrasound industry, enabling practitioners to make faster, more accurate decisions, and ultimately transforming patient care on a global scale.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。